Evidence map›Paper›PMID 35486306›Full record

ArticleJournal of neuro-oncology2022

Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.

A M Zeitlberger, P M Putora, S Hofer, P Schucht, D Migliorini, A F Hottinger, U Roelcke, H Läubli, P Spina, O Bozinov and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A M ZeitlbergerDepartment of Neurosurgery, Kantonsspital St. Gallen, St. Gallen, Switzerland.
P M PutoraDepartment of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
S HoferDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
P SchuchtDepartment of Neurosurgery, University Hospital Bern, Bern, Switzerland.
D MiglioriniDepartment of Oncology, University Hospital and University of Geneva, Geneva, Switzerland.
A F HottingerDepartment of Clinical Neurosciences and Department of Oncology, Lausanne University, Lausanne, Switzerland.
U RoelckeDepartment of Neurology, Kantonsspital Luzern, Lucerne, Switzerland.
H LäubliDepartment of Theragnostics, Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
P SpinaInstitute of Pathology, Ente Ospedalierio Cantonale Ticino, Ticino, Switzerland.
O BozinovDepartment of Neurosurgery, Kantonsspital St. Gallen, St. Gallen, Switzerland.
M WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
M C NeidertDepartment of Neurosurgery, Kantonsspital St. Gallen, St. Gallen, Switzerland.
T HundsbergerDepartment of Neurology, Kantonsspital St.Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland. thomas.hundsberger@kssg.ch.ORCID http://orcid.org/0000-0002-4419-2767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma is the most common malignant primary brain tumour in adults and driven by various genomic alterations. Next generation sequencing (NGS) provides timely information about the genetic landscape of tumours and might detect targetable mutations. To date, differences exist in the application and NGS assays used as it remains unclear to what extent these variants may affect clinical decision making. In this survey-based study, we investigated the use of NGS in adult patients with glioblastoma in Switzerland.

methodsAll eight primary care centres for Neuro-Oncology in Switzerland participated in this survey. The NGS assays used as well as the criteria for the application of NGS in newly diagnosed glioblastoma were investigated. Decision trees were analysed for consensus and discrepancies using the objective consensus methodology.

resultsSeven out of eight centres perform NGS in patients with newly diagnosed glioblastoma using custom made or commercially available assays. The criteria most relevant to decision making were age, suitability of standard treatment and fitness. NGS is most often used in fitter patients under the age of 60 years who are not suitable for standard therapy, while it is rarely performed in patients in poor general health.

conclusionNGS is frequently applied in glioblastomas in adults in Neuro-Oncology centres in Switzerland despite seldom changing the course of treatment to date.

Indexed as

Brain NeoplasmsGlioblastomaAdultDecision Support TechniquesHigh-Throughput Nucleotide SequencingHumansMiddle AgedMutationSwitzerlandDiagnosticsGlioblastomaGliomaNext generation sequencing

Identifiers

PMID35486306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.